Kanae Gamo
Co-Founder and CSO FIMECS
Kanae Gamo is leading overall research as a CSO at FIMECS, Inc. She co-founded FIMECS in 2018 as a spin-out biotech from Takeda Pharmaceutical Co., Ltd. She has expertise in many techniques of molecular biology, genetics, epigenetics and next-generation sequencing in oncology and immunology areas. During her time at Takeda, she increased responsibility of roles across target identification and validation and contributed to multiple programs. In parallel with FIMECS work, she got a Ph.D. at the University of Tsukuba in 2020. She is passionate about leveraging proprietary drug discovery platform, RaPPIDS, to unlock new biological space and accelerate pipeline progression.
Seminars
Thursday 11th June 2026
Expanding the Landscape of TPD: E3-Agnostic Approach to Unlock the E3 Ligase Space
11:30 am
- Establishing a high‑throughput, phenotype‑driven platform that enables rational E3 ligase selection and uncovers ligases not previously leveraged in TPD to expand degrader design possibilities
- Demonstrating how diverse DOS‑derived chemical scaffolds and ligase deconvolution workflows identify and optimize novel E3 ligase binders for both bifunctional degraders and molecular glue applications
- Leveraging ligases with low bone‑marrow expression to advance safer, orally bioavailable TPD therapeutics with improved selectivity, reduced myelotoxicity, and broad target applicability
